secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0000885725-23-000010
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific amends $2.75B revolver: extends maturity to 2027, switches to SOFR, resets EBITDA exclusion base
--------------------------------------------------------------------------------

- Second amendment to $2.75B revolving credit agreement extends maturity from May 2026 to May 2027 for consenting lenders.
- LIBOR replaced with Term SOFR plus credit spread adjustments for Eurocurrency Rate for Dollars.
- Reference date for excluding Cash Litigation Payments from EBITDA reset from March 31, 2021 to December 31, 2022; cap remains $1B.
- Reference date for excluding restructuring charges from EBITDA also reset to December 31, 2022; cap remains $500M.
- Amendment effective March 1, 2023; Wells Fargo remains administrative agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000010/0000885725-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572523000010/bsx-20230301.htm
  HTML page:      https://secwatch.observer/filing/0000885725-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer